SCHEMBL266492

SCHEMBL266492

CCn1cc(N(CCc2ccc(C(F)(F)F)nc2)C(=O)C(O)c2ccccc2)c(C)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.38
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SCN5A Q14524 1/20 0.33
SCN9A Q15858 1/20 0.33
PRMT5 O14744 1/20 0.33
WDR77 Q9BQA1 1/20 0.33
TACR1 P25103 2/20 0.33
KCNH2 Q12809 1/20 0.33
NR3C1 P04150 2/20 0.32
PPARD Q03181 1/20 0.32
P2RX7 Q99572 1/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2C9 P11712 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
ALDH1A1 P00352 2/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
KDM4E B2RXH2 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266491 1.00 EP300 (0.38) EP300NPC1RAB9ASCN5ASCN9A
SCHEMBL265566 0.84 EP300 (0.36) EP300SCN5ASCN9AKCNH2NR3C1
SCHEMBL265572 0.80 EP300 (0.38) EP300NPC1RAB9ASCN5ASCN9A
SCHEMBL264032 0.80 EP300 (0.38) EP300NPC1RAB9ASCN5ASCN9A
SCHEMBL264033 0.80 EP300 (0.38) EP300NPC1RAB9ASCN5ASCN9A
SCHEMBL265294 0.79 EP300 (0.34) EP300NPC1RAB9ASCN5ASCN9A
SCHEMBL265293 0.79 EP300 (0.34) EP300NPC1RAB9ASCN5ASCN9A
SCHEMBL264220 0.78 MLYCD (0.38) EP300NPC1RAB9ASCN5ASCN9A
SCHEMBL264221 0.78 MLYCD (0.38) EP300NPC1RAB9ASCN5ASCN9A
SCHEMBL263829 0.78 TACR1 (0.37) EP300NPC1RAB9ASCN5ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133909-B2 Heteroaromatic monoamides as orexinin receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-20090312314-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312314-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPSR1 EP300 1636/4885NPC1 1723/4885RAB9A 4027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.